Given the antibody-mediated pathogenesis of MG and the effectiveness of antibody-depleting therapies such as IVIg and plasma exchange, particularly during disease exacerbations, FcRn has emerged as an attractive therapeutic target for MG (Guptill et al., 2016). Here, FCGRT is linked to myasthenia gravis.